Curriculum vitae name: david j. Grdina



Yüklə 201,85 Kb.
səhifə3/3
tarix21.01.2019
ölçüsü201,85 Kb.
#101345
1   2   3

108 Amifostine: Mechanism of Action, Presentation to ODAC at FDA Meeting, Silver Springs,

Maryland, June 8, 1999.


109. Amifostine: Mechanisms of Action for Cytoprotection and Chemoprevention, Northern California

Health Care, Oakland, California, August 24, 1999.




  1. Amifostine: Mechanisms of Action for Cytoprotection and Chemoprevention, Sacramento Nurses,

Sacramento, California, August 25, 1999.


  1. Mechanisms of Cytoprotection and Chemoprevention by Amifostine, Williamsport, Pennsylvania,

October 13, 1999.


  1. Mechanisms of Cytoprotection and Chemoprevention by Amifostine, Binghampton, New York,

October 14, 1999.


  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Symposium,

ASTRO, San Antonio, Texas, October 30, 1999.


  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, International

Conference on Low-Level Radiation Injury and Medical Counter Measures, Bethesda, Maryland, November 8, 1999.


  1. Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention, Bridgeport, Connecticut, December 3, 1999.




  1. Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention, Cleveland Clinic, Cleveland, Ohio, December 10, 1999.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of Radiation Oncology, University of Wisconsin, Madison, Wisconsin, January 18, 2000.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of Radiation Oncology, Georgetown University, Washiongton D.C., January 28, 2000.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Physicians in South Florida, Fort Meyers, Florida, March 18, 2000.




  1. Amifostine for Use in Cytoprotection and the Prevention of Therapy Induced Secondary Tumors, Radiation Workshop at Round Top, M.D. Anderson Cancer Center, Round Top, Texas, April 15, 2000.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of Radiation Oncology, University of Rochester, Rochester, New York, May 10, 2000.




  1. Amifostine: the molecular mechanisms of action and novel roles in cancer treatment. XVI EACR Meeting, Chalkidiki, Greece, May 30, 2000.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Department of Radiation Oncology, New England Medical Center, Boston, Massachusetts, June 16, 2000.




  1. Mechansims of Action of Amifostine in Cytoprotection and Chemoprevention, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, June 16, 2000.




  1. Amifostine: Mechanisms of Action, Portsmouth, New Hampshire, August 30, 2000.




  1. Amifostine: The Molecular Mechanisms of Action and Novel Roles in Cancer Treatment, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, August 31, 2000.




  1. Amifostine (Ethyol): Mechanisms of Action and Novel Roles in Cancer Prevention and Treatment. 9th Meeting of the European Society for Pigment Cell Research, Perspectives for the Third Millennium, University of Ulm, Ulm, Germany, September 30, 2000.




  1. Mechanisms of Action of Amifostine in Cytoprotection and Chemoprevention, Boston Medical Center, Boston, Massachusetts, October 25, 2000.




  1. Ethyol Overview, New York Medical Group, Saggets Harbor, New York, October 26, 2000.




  1. Mechanisms Underlying the Anti-mutagenic and Anti-metastatic Effects of Amifostine, Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, Colorado, November 9, 2000.




  1. Radioprotection by Amifostine in Head and Neck Cancer, Tumor Board Conference, New Hampshire Regional Medical Center, Nashau, New Hampshire, November 31, 2000.




  1. Mechanisms of Action of Amifostine (WR2721) as an Inhibitor of Metastases Development, Armed Forces Radiobiology Research Institute, Bethesda, Maryland, January 5 , 2001.




  1. Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the Management of Radiation-Induced Toxicities, Newport Beach, California, March 31, 2001.




  1. Mechanisms of Action of Amifostine, Department of Radiation Oncology, University of Maryland, Baltimore, Maryland, April 3, 2001.




  1. Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the Management of Radiation-Induced Toxicities, Chicago, Illinois, April 20, 2001.




  1. Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the Management of Radiation-Induced Toxicities, Chicago, Illinois, April 27, 2001.




  1. Differential Activation of NFB, Gene Expression, and Protein Levels in Human Cells by Amifostine, The First Investigators’ Congress on Radioprotection, St. Croix, US Virgin Islands, June 8, 2001.




  1. Ethyol Early Development, Mechanism of Action, and Pharmacology, Novel Approaches to the Management of Radiation-Induced Toxicities, Boston, Massachusetts, June 16, 2001.




  1. Inhibition of Spontaneous Metastases Formation by Amifostine, MedImmune Medical Advisory Board Meeting, Sonoma, California, November 2, 2001.




  1. Radioprotectants: Current Status and New Directions, Symposium on: Evolving Approaches to Improve Outcomes and Minimize Toxicities in Radiation Therapy, Ingenix Medical Education, San Francisco, California, November 4, 2001.




  1. Chemopreventive and Anti-Metastatic Effects of Amifostine. MedImmune, Gaithersburg, Maryland, January 9, 2002.




  1. Novel Applications of Amifostine in Cancer Therapy and Chemoprevention, University of Texas Health Science Center at San Antonio, San Antonio, Texas, February 13, 2002.




  1. Antimetastatic Effects of Amifostine, MedImmune Oncology Cytoprotection Scientific Advisory Board Meeting, Orlando, Florida, May 17, 2002.




  1. Antimetastatic Effects of Amifostine, The 2nd International Cytoprotection Investigators’ Congress, St. Thomas, US Virgin Islands, June 7, 2002.




  1. Radiation Protectors, Sensitizers, and Combined Modality Therapies, The First Radiation Oncology Residents Course, Department of Radiation Oncology, University of Maryland, Baltimore, Maryland, August 24, 2002.




  1. Cellular Biology: Implications for the Concept of Chemoradioprotection, Symposium on Chemoradioprotection in Lung Cancer: Cellular Biology, Physiology, and Clinical Update. Seton Hall University School of Graduate Medical School Education, The American Academy of CME, and Clinical Insights, Inc., ASTRO, New Orleans, Louisiana, October 5, 2002.




  1. MnSOD Mediated Delayed Radioprotective Effect in Tumor Cells Induced by Thiols. Tumor Biology Seminar Series, Lombardi Cancer Center, Georgetown University, Washington D.C., November 15, 2002.




  1. Prevention of Mutagenesis by Phosphorothioates. Hollis-Eden Symposium on Radiation Protectors, La Jolla, California, April 15, 2003.




  1. Mechanisms of Action Underlying Amifostine’s Anti-Metastatic Effect. Division of Radiation Oncology Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, April 23, 2003.




  1. MnSOD in Delayed Radiation Resistance. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, November 17, 2003.




  1. Radioprotectors Workshop, Invited Participant, Radiation Oncology Sciences Program, National Cancer Center, Bethesda, Maryland, December 3, 2003.




  1. Aminothiols Are Anti-Mutagenic and Anti-Carcinogenic and Mediate a Delayed Radioprotective Effect. NASA Workshop on Solid Cancer Risks from Space Radiation, USRA, Center for Advanced Space Studies, Houston, Texas, January 27, 2004.




  1. Radiation Response Modifiers Symposium Organizer and Discussion Leader, 51st Annual Meeting of the Radiation Research Society, St. Louis, Missouri, April 24, 2004.




  1. Animal Models for Radiation Injury, Protection, and Therapy, Invited Participant, NIAID, Bethesda, Maryland, May 26, 2004.




  1. ASA Conference on Radiation and Health: Radiation in Realistic Environments, Interactions Between Radiation and Other Risk Modifiers: Radioprotectants: Current Status and New Directions, Beaver Creek, Colorado, June 29, 2004.




  1. Blue Ribbon Panel for NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH): Radioprotectors, Bethesda, Maryland, October 14, 2004.




  1. Stereotactic Body Radiation Therapy: Clinical, Technical and Translational Aspects: Radioprotection of Normal Tissue, Westin Galleria, Dallas, Texas, May 19, 2006.




  1. Prevention of Low Dose Radiation-Induced Genomic Instability with Clinically Relevant Non-Protein Thiols, D.O.E. Contractors Meeting, Washington, D.C., August 1, 2006.




  1. Phosphorothioates-Genomic Stabilization-Prevention of Mutagenesis and Carcinogenesis, NCI/NIH Workshop on Radiation Anti-Carcinogenesis, Workshop Chairperson, Washington, D.C., September 11, 2006.




  1. Classical Radioprotectors-The Phosphorothioates, NSBRI/NASA Radiation Medical Countermeasures Workshop, League City, Texas, October 31, 2006.




  1. Thiol-Induced Adaptive Response in Normal and Malignant Tissues, First Symposium of the Association for Ion-Beam Life Science: In Vivo Radiobiology in Cancer Research, NIRS, Chiba, Japan, June 15, 2007.




  1. A Cellular MnSOD-Mediated Adaptive Response Induced by Amifostine, Seminar Series, Section of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas Texas, Oct. 9, 2007.




  1. Thiol-Induced Delayed Radioprotective Effect and Its Implications in Radiation Oncology. Rodney Withers Radiation Research Colloquium, David Geffen School of Medicine at UCLA, UCLA Jules Stein Eye Institute, UCLA, Los Angeles, California, Oct. 27, 2007.




  1. Time, Dose, Fractionation. Department of Radiation Oncology. Residents’ Lecture, University of Maryland, Baltimore, Maryland, Dec. 16, 2008.




  1. Prevention of Low Dose Radiation-Induced Genomic Instability with Clinically Relevant Non-Protein Thiols and Vitamin E. Low Dose Radiation Research Investigators’ Workshop VIII, Department of Energy Low Dose Radiation Program, Bethesda, Maryland, April 6, 2009.




  1. Time, Dose, Fractionation. Residents’ National Review Course, University of Maryland, Baltimore, Maryland, May 29, 2009.




  1. Radiation Protectors and Sensitizers. Residents’ National Review Course, University of Maryland, Baltimore, Maryland, May 29, 2009.




  1. Time, Dose, Fractionation. Department of Radiation Oncology. Residents’ Lecture, University of Maryland, Baltimore, Maryland, January 26, 2010.




  1. Ethyol (Amifostine)-Mechanisms of Action and Novel Uses- Protection; Prevention; Anti-Metastases; Stimulation of Endogenous Anti-Oxidants. Amifostine Drs. Working Group, Istanbul, Turkey, May 6, 2010.




  1. Ethyol (Amifostine)-Mechanisms of Action and Novel Uses- Protection; Prevention; Anti-Metastases; Stimulation of Endogenous Anti-Oxidants. Amifostine Drs. Working Group, Athens, Greece, May 8, 2010.




  1. Ethyol (Amifostine)-Mechanisms of Action and Novel Uses. Drs. Working Group, Berlin, Germany, October 25, 2010.




  1. Ethyol (Amifostine)-Mechanisms of Action and Novel Uses. Drs. Working Group, Paris, France, October 26, 2010.




  1. Time, Dose, Fractionation. Resident’s National Review Course, University of Maryland, Baltimore, Maryland, May 12, 2011.




  1. Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, Resident’s National Review Course, University of Maryland, Baltimore, Maryland, May 13, 2011.




  1. LET and RBE, Resident’s National Review Course, University of Maryland, Baltimore, Maryland, May 13, 2011.




  1. Time, Dose, Fractionation. Resident’s National Review Course, University of Maryland, Baltimore, Maryland, May 5, 2012.




  1. Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, Resident’s National Review Course, University of Maryland, May 6, 2012.




  1. LET and RBE, Resident’s National Review Course, University of Maryland, Baltimore, Maryland, May 6, 2012.




  1. Time, Dose, Fractionation. University of Washington RadOnc Board Review Course, University of Washington, Seattle, Washington, May 25, 2012.




  1. Radiation Protectors, Sensitizers, and ChemoRadiation Interactions, University of Washington RadOnc Board Review Course, University of Washington, Seattle, Washington, May 25, 2012.




  1. LET, RBE, and OER, University of Washington RadOnc Board Review Course, University of Washington, Seattle, Washington, May 25, 2012.







Yüklə 201,85 Kb.

Dostları ilə paylaş:
1   2   3



Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət
gir | qeydiyyatdan keç
    Ana səhifə
Dərs
Dərslik
Guide
Kompozisiya
Mücərrəd
Mühazirə
Qaydalar
Referat
Report
Request
Review

yükləyin